Evidence map›Paper›PMID 24696140›Full record

ArticleAmerican journal of physiology. Cell physiology2014

Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue.

Romain A Colas, Masakazu Shinohara, Jesmond Dalli, Nan Chiang, Charles N Serhan

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 281 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
281citing papers in PubMed, 2 pooled it
35.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02683850 early_phase1completednot on this mapstarted 2016, after this paper: background citation

Influence of an Omega-3 SPM Supplement on Quality of Life

TypeinterventionalSponsorNational University of Natural MedicineRan2016 to 2016Enrolled44ConditionsChronic PainArmsOmega-3 SPM™ softgel
NCT03606252 nacompletednot on this mapstarted 2018, after this paper: background citation

Specialized Proresolving Mediators Evaluation in Pneumocystis Pneumonia Human Infection : Pilot Study.

TypeinterventionalSponsorUniversity Hospital, ToulouseRan2018 to 2020Enrolled66ConditionsPneumonia, PneumocystisArmsBlood sampling, urine sampling
3 · Its place in the literature

Who cites it

281 citing papers in PubMed, 2 syntheses or guidelines pooled it, 419 citations in OpenAlex.

  1. Clinical lipidomics in bacterial sepsis: a systematic review of serum and plasma evaluations.Metabolomics : Official journal of the Metabolomic Society · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Plasma lipoxin AMolecular carcinogenesis · 2017
    Trial
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

221 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Romain A ColasCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Masakazu ShinoharaCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Jesmond DalliCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Nan ChiangCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts cnserhan@zeus.bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

Resolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2020
$14.8M
Mesenchymal Stromal Cell Conditioning by Carbon MonoxideP01HL108801 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHOI, AUGUSTINE M · 2011 to 2015
$13.8M
Resolvins, protectins, and chronic pain resolution.R01NS067686 · NINDS · DUKE UNIVERSITY · PI JI, RU-RONG, SERHAN, CHARLES NICHOLAS · 2009 to 2013
$2.8M
NHLBI NIH HHS P01 HL108801NIGMS NIH HHS P01 GM095467NINDS NIH HHS R01 NS067686
6 · The paper itself

Abstract

Resolution of acute inflammation is an active process locally controlled by a novel genus of specialized pro-resolving mediators (SPM) that orchestrate key resolution responses. Hence, it is of general interest to identify individual bioactive mediators and profile their biosynthetic pathways with related isomers as well as their relation(s) to classic eicosanoids in mammalian tissues. Lipid mediator (LM)-SPM levels and signature profiles of their biosynthetic pathways were investigated using liquid chromatography-tandem mass spectrometry (LC-MS-MS)-based LM metabololipidomics. LM and SPM were identified using ≥6 diagnostic ions and chromatographic behavior matching with both authentic and synthetic materials. This approach was validated using the composite reference plasma (SRM1950) of 100 healthy individuals. Using targeted LM metabololipidomics, we profiled LM and SPM pathways in human peripheral blood (plasma and serum) and lymphoid organs. In these, we identified endogenous SPM metabolomes, namely, the potent lipoxins (LX), resolvins (Rv), protectins (PD), and maresins (MaR). These included RvD1, RvD2, RvD3, MaR1, and NPD1/PD1, which were identified in amounts within their bioactive ranges. In plasma and serum, principal component analysis (PCA) identified signature profiles of eicosanoids and SPM clusters. Plasma-SPM increased with omega-3 and acetylsalicylic acid intake that correlated with increased phagocytosis of Escherichia coli in whole blood. These findings demonstrate an approach for identification of SPM pathways (e.g., resolvins, protectins, and maresins) in human blood and lymphoid tissues that were in amounts commensurate with their pro-resolving, organ protective, and tissue regeneration functions. LM metabololipidomics coupled with calibration tissues and physiological changes documented herein provide a tool for functional phenotypic profiling.

Indexed as

MetabolomicsAdultAgedAged, 80 and overAnti-Inflammatory AgentsAspirinBiomarkersChromatography, LiquidDocosahexaenoic AcidsEscherichia coliFatty Acids, EssentialFemaleHumansInflammationInflammation MediatorsLipidsAnti-Inflammatory AgentsAspirinBiomarkersDocosahexaenoic AcidsFatty Acids, EssentialInflammation MediatorsLipidsLipoxinseicosanoidsinflammationresolutionresolvins

Identifiers

PMID24696140
PMCPMC4080182
OpenAlexW2039850229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.